nephrology

News

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.

News

Bayer's Kerendia has hit the spot in another phase 3 trial that could fuel its already rapid growth as a chronic kidney disease treatment.

News

Vertex's bid to expand beyond cystic fibrosis has taken a big step forward with phase 3 data for povetacicept in severe kidney disorder IgAN.

News

Novo Nordisk has boosted its pipeline by paying $340m upfront for rights to an Omeros drug for PNH and other rare blood and kidney disorders.

News

An NHS trust in England is starting a pilot study of a digital health platform that promises to improve the care of people with kidney disease.

News

Otsuka and Vera both have new phase 3 data on drugs for kidney disease IgA nephropathy, but can they make a mark in an increasingly crowded market?